

Supplementary Material

Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication

Johan Dalén ¹, Axel Svedbom ¹, Emma Hernlund ¹, Tor Olofsson ², Christopher M. Black ³

¹*ICON plc, Stockholm, Sweden*

²*Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden*

³*Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, United States*

Author for correspondence

Christopher M. Black ()

Director, Center for Observational and Real-World Evidence (CORE)

Merck & Co., Inc.

126 East Lincoln Ave., Rahway, NJ USA 07065

Phone: +1 (732) 397-3544

E-mail: christopher.black2@merck.com

Table S1 Bivariate and multivariate Cox proportional hazards models of persistence with subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment by indication

RA								
	Bivariate models				Multivariate model			
	DF	Chi-Sq.	HR	p-value	DF	Chi-Sq.	HR	p-value
Sex (ref=Female)	1	19.325	0.866	<0.0001	1	14.342	0.883	0.0002
Age at index date	1	29.521	0.995	<0.0001	1	16.362	0.991	<0.0001
SC-TNFi treatment	3	24.690	-	<0.0001	3	24.762	-	<0.0001
Adalimumab vs Golimumab	1	21.887	1.249	<0.0001	1	20.868	1.243	<0.0001
Certolizumab Pegol vs Golimumab	1	15.153	1.216	<0.0001	1	16.515	1.228	<0.0001
Etanercept vs Golimumab	1	12.742	1.156	0.0004	1	11.436	1.148	0.0007
Specialized outpatient visits	1	43.414	1.017	<0.0001	1	16.817	1.014	<0.0001
Specialized outpatient visits for IA	1	11.050	1.015	0.0010	1	0.222	1.003	0.6379
Inpatient visits	1	16.502	1.072	<0.0001	1	2.028	1.032	0.1544
Inpatient visits for IA	1	8.159	1.131	0.0043	1	0.673	1.044	0.4120
Age adjusted CCI exc RA comp.	1	15.070	0.962	<0.0001	1	2.218	1.033	0.1364
Steroid use (ref="Yes")	1	6.776	0.922	0.0088	1	6.820	0.920	0.0090
NSAIDs (ref="Yes")	1	4.535	1.063	0.0353	1	6.439	1.077	0.0112
csDMARDs (ref="Yes")	1	43.982	1.367	<0.0001	1	39.559	1.350	<0.0001

PsA								
	Bivariate models				Multivariate model			
	DF	Chi-Sq.	HR	p-value	DF	Chi-Sq.	HR	p-value
Sex (ref=Female)	1	132.644	0.625	<0.0001	1	108.382	0.649	<0.0001
Age at index date	1	0.771	1.001	0.3798	1	0.438	0.997	0.5082
SC-TNFi treatment	3	29.893	-	<0.0001	3	21.709	-	<0.0001
Adalimumab vs Golimumab	1	17.492	1.302	<0.0001	1	13.326	1.261	0.0003
Certolizumab Pegol vs Golimumab	1	24.448	1.565	<0.0001	1	18.174	1.475	<0.0001
Etanercept vs Golimumab	1	18.481	1.294	<0.0001	1	11.334	1.225	0.0008
Specialized outpatient visits	1	21.952	1.017	<0.0001	1	9.019	1.013	0.0027
Specialized outpatient visits for IA	1	0.155	0.997	0.6937	1	4.088	0.982	0.0432
Inpatient visits	1	12.891	1.100	0.0003	1	0.083	1.01	0.7736
Inpatient visits for IA	1	5.023	1.266	0.025	1	1.951	1.179	0.1625
Age adjusted CCI exc RA comp.	1	2.099	1.024	0.1488	1	0.115	1.014	0.7345
Steroid use (ref="Yes")	1	37.347	0.782	<0.0001	1	18.292	0.837	<0.0001
NSAIDs (ref="Yes")	1	1.221	1.051	0.2767	1	0.234	1.022	0.6286
csDMARDs (ref="Yes")	1	3.279	1.095	0.0727	1	3.682	1.104	0.0550

AS/uSpA								
	Bivariate models				Multivariate model			
	DF	Chi-Sq.	HR	p-value	DF	Chi-Sq.	HR	p-value
Sex (ref=Female)	1	144.202	0.635	<0.0001	1	126.554	0.648	<0.0001
Age at index date	1	3.657	0.997	0.0558	1	7.584	0.993	0.0059
SC-TNFi treatment	3	33.941	-	<0.0001	3	27.157	-	<0.0001
Adalimumab vs Golimumab	1	23.228	1.283	<0.0001	1	19.318	1.257	<0.0001
Certolizumab Pegol vs Golimumab	1	9.189	1.310	0.0024	1	8.250	1.294	0.0041
Etanercept vs Golimumab	1	30.651	1.337	<0.0001	1	23.742	1.294	<0.0001
Specialized outpatient visits	1	8.988	1.011	0.0032	1	0.452	1.003	0.5014
Specialized outpatient visits for IA	1	0.011	1.001	0.9164	1	0.041	0.998	0.8390
Inpatient visits	1	9.258	1.075	0.0023	1	2.088	1.042	0.1485
Inpatient visits for IA	1	1.214	1.09	0.2706	1	0.001	1.003	0.9704
Age adjusted CCI exc RA comp.	1	0.876	0.985	0.3460	1	1.779	1.038	0.1823
Steroid use (ref="Yes")	1	20.757	0.839	<0.0001	1	8.716	0.885	0.0032
NSAIDs (ref="Yes")	1	3.936	1.103	0.050	1	2.561	1.084	0.1095
csDMARDs (ref="Yes")	1	3.904	1.078	0.0467	1	11.435	1.145	0.0007

Note: RA for rheumatoid arthritis; PsA for Psoriatic arthritis; AS/uSpA for ankylosing spondylitis/unspecified spondyloarthritis; DF for Degrees of Freedom; HR for Hazard Ratio; Chi-sq. for Chi-square; IA for Inflammatory Arthritis; CCI for Charlson comorbidity index; NSAIDs for Non-Steroidal Anti-Inflammatory Drugs; csDMARDs for conventional systemic disease modifying anti-rheumatic drugs.